A Recap: Investing in Pharma Technology

A Recap: Investing in Pharma Technology

Rob Larson, Jordan Abrams • February 17, 2026
Rob Larson, Jordan Abrams • February 17, 2026

Share

Grant Thornton Stax recently partnered with Raymond James for a healthcare-focused breakfast discussion centered on PE investment opportunities in pharma technology. The session brought together investors to explore where capital is flowing across the drug development lifecycle and how to evaluate scalable, tech-enabled platforms in a market that continues to evolve.


The central theme of the discussion was the continued investor interest in outsourced pharma tech and services, which ranked among the top areas of thematic focus in our recent survey of 200 mid-market and large-cap investors. Attendees discussed how technology is becoming increasingly embedded throughout preclinical development, clinical trials, the regulatory approval process, and commercialization.


Thematic areas of focus included AI-enabled discovery tools and lab automation in early R&D, site-focused clinical trial infrastructure, digital supply chain and regulatory platforms, and commercialization software targeting HCPs.

Grant Thornton Stax and Raymond James covered: 

  • Where AI is disruptive and can be an opportunity in pharma drug development
  • How regulatory pressure may be impacting pharma marketing spend
  • How changes to the Veeva and Salesforce relationship can guide investors for areas of opportunity
  • Recent valuation trends and how its impacting the current market buyside and sell-side dealmaking
  • Assets we expect to come to market in the near-term and later in 2026

Overall, the breakfast provided practical insights into evaluating the pharma tech investment ecosystem. With deep experience across preclinical, clinical development, and commercialization engagements, Grant Thornton Stax continues to support investors and management teams as they identify and scale high-growth platforms across the life sciences technology ecosystem.


For further discussion, we welcome you to connect with our dedicated life sciences team.

Image of Rob Larson

Managing Director, Healthcare

Image of Jordan Abrams

Jordan Abrams

Director

Image of Alex Despo

Alex Despo

Managing Director, Raymond James

Read More

AI Is Everywhere in Public Safety Tech. What Will Separate the Winners?
By Chen Liu • November 13, 2026
Following the 2026 International Association of Chiefs of Police (IACP) Conference, Chen Liu shares five key takeaways on what will distinguish the leading providers. Read the full list here.
Grant Thornton Advisors Completes Acquisition of CBIZ
November 3, 2026
Grant Thornton Advisors LLC, New Mountain Capital, and CBIZ, Inc. today announced that Grant Thornton Advisors completed its acquisition of CBIZ. Read the full announcement here.
5 Key Takeaways from the Goodwin Pharma Services Symposium
By Jordan Abrams • October 30, 2026
Following the Goodwin Pharma Services Symposium, Jordan Abrams shares five key takeaways on the investment landscape for pharma services. Read his full list here.
Featured by ION Analytics: Private equity pays up for scale amid youth-enrichment platform scarcity
By Luke Scheibel • October 21, 2026
Luke Scheibel was interviewed by ION Analytics, where he shared his perspective on PE's rising interest in youth sports and the evolving investment considerations around them. Read more.
Paul Edwards & Robert Lytle Named Top PE Consultants & Leaders 2026
By Paul Edwards & Robert Lytle • October 21, 2026
Grant Thornton Stax is pleased to announce the naming of both Paul Edwards and Robert Lytle to The Consulting Report's Top Private Equity Consultants and Leaders of 2026. Read more here.
Feat. by Reuters: Chinese automakers make tech-led pitch for EU car market
By Brad Kuntz • October 16, 2026
Brad Kuntz was interviewed by Reuters to discuss how Chinese automakers are reshaping traditional perceptions of luxury in the EU automotive industry. Read the full story here.
Show More